Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls

Natasha Amrita Satkunam, MBBS, MSc, Johnny Mahlangu, MD, Christoph Bidlingmaier, MD PD, Dr. MD, Maria Eva Mingot-Castellano, PhD, Meera B. Chitlur, MD, Patrick F. Fogarty, MD, Adam Cuker, MD MS, Maria Elisa Mancuso, MD PhD, Pal André Holme, PhD MD, Julie Grabell, BA, CCRP, Wilma Hopman, MA, Prasad Mathew, MD, Paula D. James, MD

Blood (2016) 128 (22): 875.

https://doi.org/10.1182/blood.V128.22.875.875

Published: 2016

Journal Articles

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

Amy Shapiro, MD, John Pasi, MBChB, PhD, FRCP, FRCPath, Johnny Mahlangu, MD, David J. Perry, MD, PhD, FRCP, FRCPath, Jerry S Powell, MD, Margaret V. Ragni, MD, MPH, Leonard A. Valentino, MD, FAAP, Margareth Ozelo, MD, PhD, Karen Nugent, MSc, Shuanglian Li, MD, PhD, Aoife Brennan, MB, BCh, BAO, MMSC, Glenn F Pierce, MD, PhD, Geoffrey Allen, MD

Blood (2013) 122 (21): 2350.

https://doi.org/10.1182/blood.V122.21.2350.2350

Published: 2013

Journal Articles

Pharmacokinetics Of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Pediatric Subjects With Hemophilia A: An Interim Analysis Of The Kids A-LONG Study

Guy Young, MD, Johnny Mahlangu, MD, Beatrice Nolan, MB, MRCPI, FRCPATH, Simon Brown, MD, FRACP, FRCPA, MBBS, FRCP, FRCPath, Leonard A. Valentino, MD, FAAP, Raina Liesner, MA, MBBChir, MD, FRCP, FRCPath, MRCPCH, Yingwen Dong, PhD, Lei Diao, PhD, Haiyan Jiang, PhD, Karen Nugent, MSc, Glenn F. Pierce, MD, PhD, Geoffrey Allen, MD

Blood (2013) 122 (21): 3609.

https://doi.org/10.1182/blood.V122.21.3609.3609

Published: 2013

Journal Articles

Immune Tolerance Induction (ITI) in Adults with Congenital Hemophilia: A Multicenter Experience

Rebecca Kruse-Jarres, MD/MPH, Maria Elisa Mancuso, MD, PhD, Eva Mingot Castellano, MD, Johnny Mahlangu, MD

Blood (2012) 120 (21): 1123.

https://doi.org/10.1182/blood.V120.21.1123.1123

Published: 2012

Journal Articles

A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.

Johnny Mahlangu, MD, Tatiana A. Andreeva, MD, Donald Macfarlane, MD, PhD, Mark T. Reding, MD, Christopher Walsh, MD, Bruce Ritchie, MD, Nadia Ewing, MD, Craig M. Kessler, MD, Christine Kempton, MD, Edward Libby, MD, Nadezda Zozulya, MD, Amy D. Shapiro, MD, Jean St-Louis, MD, Indira Warrier, MD, W. Keith Hoots, MD, Ralph A. Gruppo, MD, Josef N. Mueksch, MD, MBA

Blood (2007) 110 (11): 783.

https://doi.org/10.1182/blood.V110.11.783.783

Published: 2007

NARROW

Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

Pharmacokinetics Of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Pediatric Subjects With Hemophilia A: An Interim Analysis Of The Kids A-LONG Study

Immune Tolerance Induction (ITI) in Adults with Congenital Hemophilia: A Multicenter Experience

A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.

Email alerts

ASH Publications

American Society of Hematology

Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

Pharmacokinetics Of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Pediatric Subjects With Hemophilia A: An Interim Analysis Of The Kids A-LONG Study

Immune Tolerance Induction (ITI) in Adults with Congenital Hemophilia: A Multicenter Experience

A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only